Tag: FDA-approved

April 24, 2018

Tetra Bio-Pharma Signs Commercialization Deal for PPP001 in Israel

Tetra Bio-Pharma announced the signing of a first binding term sheet for the marketing and distribution of its product PPP001...
April 12, 2018

Illumina and Loxo Oncology Form Collaboration, Share Prices Increase

Illumina and Loxo have teamed up to develop and commercialize a multi-gene panel for broad tumor profiling for cancer indications.
April 12, 2018

EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™

EyePoint Pharmaceuticals (NASDAQ:EYPT) a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S. Patent and Trademark Office...
April 10, 2018

Investing in Glioblastoma Treatments

Glioblastoma tumors are one of the most aggressive forms of cancer and yet have very few treatments. Here's how investing...
April 10, 2018

Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Loxo Oncology (Nasdaq:LOXO) and Illumina (Nasdaq:ILMN) announced a global strategic partnership to develop and commercialize a multi-gene panel for broad...
April 10, 2018

VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today...
April 5, 2018

VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today...